Diagnostic applications of nuclear medicine: Lung and mediastinal tumors

Elite Arnon-Sheleg, Thida Win, Ora Israel, Ludmila Guralnik, Mor Moskovitz, Simona Ben-Haim

Research output: Chapter in Book/Report/Conference proceedingChapterpeer-review


While CT and MRI provide high-resolution anatomic assessment of lung and mediastinal malignancies, [18F]FDG imaging is superior in differentiating benign from malignant lymphadenopathy and in the detection of distant metastases. Pre-therapy assessment with [18F]FDG PET/CT can provide important prognostic information. In addition, [18F]FDG PET/CT can eliminate about half of futile thoracotomies and is therefore recommended for staging of lung and mediastinal tumors. [18F]FDG imaging is also indicated in the diagnosis of recurrent disease and in monitoring treatment. [18F]FDG PET/CT has been introduced for radiation planning, enabling refining treatment volumes to allow increased dose in target volume and reduced toxicity to nontarget tissues. Although [18F]FDG is the most widely used tracer in oncology, other PET tracers are evaluated with specific clinical and research goals and may have a future role in the management of lung malignancies.

Original languageEnglish
Title of host publicationNuclear Oncology
Subtitle of host publicationFrom Pathophysiology to Clinical Applications
PublisherSpringer International Publishing
Number of pages67
ISBN (Electronic)9783031054945
ISBN (Print)9783031054938
StatePublished - 4 Oct 2022

Bibliographical note

Publisher Copyright:
© Springer Nature Switzerland AG 2022.


  • Lung and mediastinal tumor imaging
  • Lung cancer
  • Staging of lung and mediastinal tumors
  • [F]FDG imaging in lung cancer


Dive into the research topics of 'Diagnostic applications of nuclear medicine: Lung and mediastinal tumors'. Together they form a unique fingerprint.

Cite this